Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.
Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.
As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.
Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.
For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.
Sera Prognostics (NASDAQ: SERA) has announced the pricing of a $50 million public offering, consisting of 1,250,000 shares of Class A common stock at $4.00 per share and pre-funded warrants to purchase 11,250,000 shares at $3.9999 per warrant. The company has granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares.
The offering, expected to close on February 12, 2025, is being managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets. Sera plans to use the proceeds to expand commercial infrastructure in the United States, prepare for European Union expansion, fund studies for PreTRM test adoption, including a potential FDA submission, and for general corporate purposes.
Sera Prognostics (NASDAQ: SERA) has announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase additional shares up to 15% of the total offering. Jefferies, TD Cowen, William Blair are acting as joint book-running managers, with RBC Capital Markets as a bookrunner.
The net proceeds will be used to:
- Expand commercial infrastructure in the United States
- Accelerate European Union expansion preparations
- Fund studies to increase PreTRM test adoption
- Potential FDA submission for broad PreTRM test approval
- General corporate purposes
The offering is subject to market conditions, with no guarantee of completion or final terms. A shelf registration statement on Form S-3 was previously filed and declared effective by the SEC.
Sera Prognostics (NASDAQ: SERA) has announced plans to host a virtual R&D Day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. The event will feature presentations from the company's management team and Dr. Brian Iriye, the principal investigator of the pivotal PRIME study from the High-Risk Pregnancy Center in Las Vegas.
The event will showcase results from the PRIME study (Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs) and include a Q&A session. Participants can join via conference call using US domestic number (800) 836-8184 or international number (646) 357-8785, or through the webcast link available on Sera's website. The webcast recording will be archived on the Investors page for one year.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. President and CEO Zhenya Lindgardt will deliver a presentation on January 16 at 9:45 a.m. PT, providing company updates and discussing recent achievements.
The company, which specializes in providing innovative pregnancy biomarker information to healthcare professionals and patients to enhance maternal and neonatal health, will make the presentation available via live webcast. Interested parties can access both the live presentation and its replay through the Investors section of Sera's website at www.seraprognostics.com.
Sera Prognostics (NASDAQ: SERA) announced that its PRIME study results will be presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025. Dr. Brian Iriye, principal investigator, will deliver the presentation focusing on how the PreTRM test, which identifies women at higher risk of preterm delivery, combined with targeted clinical interventions affects neonatal outcomes.
The study's enrollment was stopped in December 2023 after achieving at least one primary endpoint with statistical significance. The PRIME abstract was selected as one of five late-breaking presentations and is expected to be published in mid-January 2025. The annual Pregnancy Meeting™ is considered the world's leading conference on pregnancy, featuring various educational and scientific programs.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation will take place on December 5, 2024 at 2:30 p.m. ET, featuring President and CEO Zhenya Lindgardt in a fireside chat to provide company updates and discuss recent achievements. The presentation will be available via live webcast and replay on the company's investor website.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The presentation will take place on November 21, 2024, at 4:00 p.m. ET. President and CEO Zhenya Lindgardt will engage in a fireside chat to provide company updates and discuss recent achievements. The presentation will be available via live webcast and replay on the company's investor relations webpage.
Sera Prognostics reported its third quarter 2024 financial results, marking a revenue of $29,000, a drop from $42,000 in the same period of 2023. Operating expenses increased by 8% to $8.9 million, driven by product development and future sales initiatives. Net loss for the quarter was $7.9 million, up from $7.2 million in Q3 2023. Key activities included the analysis of the PRIME study data, an awareness campaign featuring TV programs with Dennis Quaid and Meg Ryan, and the introduction of home sample collection for PreTRM® testing. The company also launched a predictive analytics tool in beta testing and strengthened its commercial team. The transition to ambient whole blood collection aims to enhance scalability and unit economics. Sera Prognostics anticipates a sales inflection point with the publication of PRIME study results and expanded awareness of its test-and-treat strategy.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced it will release its third quarter fiscal year 2024 financial results on November 6, 2024, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. A press release with financial results will be distributed before the call. The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The presentation is scheduled for September 11, 2024, at 10:00 a.m. ET. Zhenya Lindgardt, President and CEO, will deliver a company update and discuss recent achievements.
Sera Prognostics specializes in improving maternal and neonatal health by providing innovative pregnancy biomarker information to healthcare professionals and patients. Investors and interested parties can access a live webcast of the presentation, as well as a replay, on the company's website at www.seraprognostics.com under the Investors page.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is Sera Prognostics' main product?
Where is Sera Prognostics headquartered?
What is the mission of Sera Prognostics?
Who are some of the major investors in Sera Prognostics?
What recent financial milestone has Sera Prognostics achieved?
How does the PreTRM® Test work?
What are the benefits of the PreTRM® Test?
What strategic partnerships does Sera Prognostics have?
What are the company's future plans for expanding its product offerings?
What challenges does Sera Prognostics face?
